Virus inactivation in the 1990s - And into the 21st century: Part 3a, plasma and plasma products (heat and solvent/detergent treatments)

BioPharm

Volumn 15, Issue 9, 2002, Pages 28-42

  Sofer, Gail ^a  

^a BioReliance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; SOLVENT;

BIOTECHNOLOGY; HEATING; NONHUMAN; PASTEURIZATION; PLASMA; REVIEW; VIRAL CONTAMINATION; VIRUS INACTIVATION;

EID: 0036712920     PISSN: 10408304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Virus inactivation in the 1990s - And into the 21st century: Skin, bone, and cells
2. Virus inactivation in the 1990s - And into the 21st century: Red blood cells and platelets
3. Evaluation of protein modification during anti-viral heat bioprocessing by electrospray ionization mass spectrometry
4. Reducing the risk of infection from plasma products: Specific preventative strategies
5. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates
6. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy
7. Effect of terminal (Dry) heat treatment on non-enveloped viruses in coagulation factor concentrates
8. Detection of parvovirus B19 in donated blood: A model system for screening by polymerase chain reaction
9. Development and small-scale production of a severely heated factor VIII concentrate
10. Von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (High Purity)
11. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization
12. Improvement of virus safety of an S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C,
13. In vitro and in animal model studies on a double virus-inactivated factor VIII concentrate
14. Inactivation of viruses found with plasma proteins
15. Current safety of clotting factor concentrates
16. Inactivation of hepatitis A virus in plasma products by vapor heating
17. 50 assay
18. Viral inactivation and partitioning in the manufacture of coagulation factor concentrates
19. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment
20. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin
21. Chromatographic removal and heat inactivation of hepatitis B virus during the manufacture of human albumin
22. Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin
23. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography
24. Inactivation of hepatitis A virus in plasma products by vapor heating
25. 50 assay
26. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII Concentrate
27. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation
28. Heat stability of parvovirus B19: Kinetics of inactivation
29. Inactivation of viruses related to hepatitis C virus by pasteurization in human plasma derivatives
30. Virus safety of human immunoglobulins: Efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure
31. Inactivation of retroviruses in biologicals manufactured for human use
32. Characterisation and virus safety of alpha 1-proteinase inhibitor
33. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins
34. Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride
35. Stability of hepatitis A virus
36. Viral safety of a new highly purified factor VIII (OCTATE)
37. Virus validation experiments on the production process of OCTAVI SDPlus
38. Standardization and the viral clearance industry
39. Pasteurization of Cohn fraction V products: Effect of pH on viral inactivation efficacy
40. HAV inactivation by pasteurization: Validation of virus removal and inactivation
41. Human coagulation factor IX: Assessment of thrombogenicity in animal models and viral safety
42. Inactivation of viruses in blood with aluminum phthalocyanine derivatives
43. Enhancement in the safety of immune globulins prepared from high-risk plasma
44. High-temperature short-time heat inactivation of HIV and other viruses in human blood plasma
45. Inactivation and clearance of viruses during the manufacture of high purity factor IX
46. Viral inactivation of fresh frozen plasma
47. Viral safety of solvent-detergent treated blood products
48. Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin
49. Ultrapure plasma factor VIII produced by anti-F VIII C immunoaffinity chromatography and solvent/detergent viral inactivation: Characterization of the method M process and hemofil M antihemophilic factor (Human)
50. Successful clinical use of a plasma-derived, dual virus inactivated FVIII concentrate incorporating s/d and dry heat treatment
51. Solvent/detergent treatment of human plasma - A very robust method for virus inactivation: Validated virus safety of OCTAPLAS
52. The Use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation
53. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma
54. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma
55. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma
56. Specific inactivation of viruses which can potentially contaminate blood products
57. Virus validation of plasma-derived products produced by pharmacia, with particular reference to immunoglobulins
58. Characterisation of a chromatographically produced anti-D immunoglobulin product
59. Viral inactivation of intramuscular immune serum globulins
60. Use of vegetable-derived tween 80 for virus inactivation by solvent/detergent treatment